1. Inicio
  2. Proyectos y Estudios
  3. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma.

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma.

Datos básicos

ENSAYO CLÍNICO INCMOR0208-301 2020-004407-13 HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE Año de incio: 2022 Año de finalización: 2023

Objetivos del proyecto

Objetivo Principal: To compare the efficacy of tafasitamab and lenalidomide in addition to rituximab to the efficacy of placebo and lenalidomide in addition to rituximab in participants with relapsed/ refractor (R/R) FL. Objetivos Secundarios: * To compare the efficacy of tafasitamab and lenalidomide in addition to rituximab versus placebo and lenalidomide in addition to rituximab in the overall population (FL and MZL) * To compare the efficacy of tafasitamab and lenalidomide in addition to rituximab versus placebo and lenalidomide in addition to rituximab in the FL population.

Documentos

  • No hay documentos

Participantes

Ver todos los Investigadores

Grupos

Financiadores - Promotores

INCYTE CORPORATION

Cita

Compartir